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Abstract — Aims: To explore the effect of baclofen in a dose of 20 mg three times per day, compared with the already studied dose
of 10 mg three times per day, in the treatment of alcohol dependence. Methods: We present a secondary analysis of a 12-week
double-blind, placebo-controlled, randomized clinical trial with two doses of baclofen, specifically 10 mg t.i.d. and 20 mg t.i.d. Out
of 94 subjects consecutively screened, 42 were randomized into the study. Fourteen of the 42 patients were randomly allocated to
placebo, 14 to the group treated with baclofen 10 mg t.i.d. (B10 mg) and 14 to the group treated with baclofen 20 mg t.i.d. (B20
mg). Results: Compared with patients allocated to placebo, patients allocated to the B10 mg group had a 53% reduction in the
number of drinks per day (P < 0.0001) and patients allocated to the B20 mg group had a 68% reduction in the number of drinks per
day (P < 0.0001), with respect to the number of drinks per day during the 28 days before randomization. The effect of baclofen 20
mg t.i.d. was greater than that of baclofen 10 mg t.i.d. (P = 0.0214, Wald test) showing a dose–effect relationship. Both doses of
baclofen were well tolerated. Conclusion: This is provisional evidence of a dose–response effect for baclofen in the treatment of
alcohol dependence.
INTRODUCTION
Alcohol dependence afflicts nearly 10% of the population,
both in the USA and in Europe, and causes serious morbid-
ity and mortality (U.S. Department of Health and Human
Services, 2000). Treatment of alcohol dependence consists of
psychological, social and pharmaceutical interventions
(Addolorato et al., 2005; Swift and Leggio, 2009). Only a
few medications are approved in the USA and in Europe for
this indication and their efficacy is less than optimal. In the
last two decades, several further medications, including
baclofen, have been tested and/or are under investigation as
new pharmacotherapies for alcohol dependence.
Baclofen is a γ-aminobutyric acid (GABA) B-receptor
agonist and at present is approved to treat spasticity.
Preclinical experiments have demonstrated that adminis-
tration of baclofen in alcohol-preferring rats affects several
alcohol-seeking behaviours: acquisition and maintenance of
alcohol-drinking behaviour, alcohol intake after a period
of alcohol abstinence (relapse-like drinking), oral self-
administration of alcohol and also modifies motivational
cues for alcohol (reviewed by Colombo et al., 2004;
Maccioni and Colombo, 2009).
Human studies with alcohol-dependent patients have
shown the safety and the efficacy of baclofen as a pharma-
cotherapy for alcohol dependence. The ability of baclofen
(10 mg t.i.d.) to reduce alcohol craving and intake and
promote alcohol abstinence in alcohol-dependent individuals
was observed in open-label studies (Addolorato et al., 2000;
Flannery et al., 2004) as well as in other clinical studies
where baclofen (10 mg t.i.d.) was administered open-label
(Leggio et al., 2008a,b).
A 4-week double-blind, placebo-controlled, randomized
clinical trial with 39 alcohol-dependent subjects assigned to
receive baclofen (10 mg t.i.d.) or placebo showed a
significantly higher percentage of subjects achieving and
maintaining total alcohol abstinence in the baclofen group,
compared with the placebo group (Addolorato et al., 2002).
Similarly, there was a significant reduction in alcohol
craving scores in the baclofen group compared with placebo.
These findings were confirmed in a larger 12-week random-
ized clinical trial with baclofen (10 mg t.i.d.) vs. placebo,
which enrolled a more severe population, alcohol-dependent
patients with liver cirrhosis (Addolorato et al., 2007).
Consistent with the previous observation, this study showed
a significant effect of baclofen, compared with placebo, in
reducing alcohol consumption and craving and in promoting
total alcohol abstinence. In contrast, another 12-week ran-
domized clinical trial with baclofen reported no significant
differences in heavy drinking and craving between baclofen
and placebo (Garbutt et al., 2010). It has been highlighted
how the latter trial enrolled a less severe population of alco-
holics than previous studies with baclofen (Flannery and
Garbutt, 2008; Leggio et al., 2010). The difference in sever-
ity has been suggested as a possible explanation of the differ-
ences in outcomes between the last study and the previous
ones (Flannery and Garbutt, 2008; Garbutt, 2009; Garbutt
et al., 2010; Leggio et al., 2010).
All studies reported above tested baclofen at the dose of 10
mg t.i.d. However, anecdotal reports have hypothesized the
ability of high doses of baclofen (up to 140 and 270 mg/day)
to reduce alcohol craving and consumption (Ameisen, 2005;
Bucknam, 2007). Moreover, baclofen at the dose of 20 mg t.i.
d. has been already tested in other addictions, i.e. cocaine
dependence (Kahn et al., 2009; Shoptaw et al., 2003).
Thus, we planned a 12-week clinical trial to test two doses
of baclofen, specifically 10 mg t.i.d. and 20 mg t.i.d. Initially,
this study was planned as a multi-site, double-blind, placebo-
controlled, randomized trial, named International Baclofen
Interventional Study (IBIS) and involving sites in Europe and
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in Australia. However, out of five centers that initially agreed
to participate, only three joined the study, specifically our site
at Catholic University of Rome (Italy) and sites located in
Austria and Australia. However, in the Austrian and
Australian sites, there was a large loss at follow-up of subjects
and unavailability of all outcome measures at all time points.
These factors led to the decision of not analysing the
Australian and Austrian datasets because of intractable meth-
odological limitations (Carpenter and Kenward, 2007;
Piantadosi, 2005). Thus, statistical analysis was conducted
only on the Italian data set. The main outcomes of this
primary analysis were heavy drinking days (HDD), abstinent
days (AD) and craving score. The secondary outcomes were
time to first lapse and time to first relapse. Analysis of these
pre-defined outcome measures did not show significant differ-
ence between groups, possibly related to the lack of statistical
power (i.e. no differences were found in HDD or in AD for
baclofen 10 mg t.i.d. v. placebo, or for baclofen 20 mg t.i.d.
v. placebo). Nor were there significant differences in HDD or
in AD between the baclofen groups. No significant modifi-
cation of HDD in relation to time nor in relation to interaction
treatment time was found. A more detailed description of the
planned outcomes is reported elsewhere (Addolorato and
Leggio, 2010). Here, we report the results of a secondary
analysis, which was also conducted only on the Italian sample
of 42 patients. Specifically, while the planned outcome was
based on the reduction of heavy drinking, this post hoc analy-
sis used the number of drinks per day across the entire study
period as the outcome variable.
PATIENTS AND METHODS
Patients
Ninety-four alcohol-dependent patients referred to the
Alcohol Treatment Unit of our Institute of Internal Medicine
(‘Agostino Gemelli’ Hospital, Catholic University of Rome,
Italy) were assessed for eligibility between January 2006 and
December 2007. Table 1 shows inclusion and exclusion cri-
teria. The study protocol was approved by the Ethics
Committee of the ‘Agostino Gemelli’ Hospital of the
Catholic University of Rome (Italy), where the study was
conducted. All participants provided written informed
consent. The trial was registered in the European Clinical
Trials Database (EudraCT Number: 2006-000713-37).
Methods
We performed a 12-week, three-arm parallel, double-blind,
randomized clinical trial with two doses of baclofen (10 mg
t.i.d. or 20 mg t.i.d.) or placebo. Participants were screened
(Week 00 visit) and, if eligible they were randomized (Week
01 visit). Randomized participants were seen as outpatients
in our hospital every week during the first month (Week 02,
03 and 04 visits), and then every other week during the rest
of the trial (Week 06, 08, 10 and 12 visits). Four weeks after
the last medication dose, a follow-up visit (Week 16) was
performed.
After a brief pre-screening, participants were scheduled for
a more comprehensive screening visit. At the screening visit,
diagnosis of alcohol dependence was performed according to
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV)-TR criteria (American Psychiatric Association,
2000). Other major Axis I psychiatric disorders including
other substance dependence (except nicotine dependence)
were exclusion criteria (diagnosed using the Mini
International Neuropsychiatric Interview (Sheehan et al.,
1999). Relevant medical history was recorded and physical
examination was performed. The number of standard drinks
consumed by each patient in the 28-day period before the
screening visit was recorded using the Timeline Follow Back
Table 1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Age range 18–60 years (inclusive) • Clinically significant medical disease that might interfere with the evaluation
of the study medication or that might represent a safety concern
• Diagnosis of alcohol dependence according to DSM IV-TR • Clinical significant psychiatric illness including any psychotic disorders,
bipolar disorder, severe depression, suicidal ideation, substance use
disorders other than alcohol and nicotine dependence or cannabis abuse
• Alcohol intake of at least 2 HDDa per week on average and an average
overall consumption of 21 drinks per week or more for men and 14 drinks
per week or more for women in the 4 weeks before enrolment
• Abstinence from alcohol for >10 days prior to randomization day
• Ability to understand and sign written informed consent • Concurrent use of psychotropic medication, including antidepressant, mood
stabilizers, antipsychotics, anxiolytics or hypnotics
• Ability to refrain from drinking for at least 3 days prior to randomization
day
• Concurrent use of anticonvulsants, insulin or oral hypoglycaemics
• Desire to achieve abstinence or to greatly reduce alcohol consumption • AST and/or ALT levels >3 times of UNL, or bilirubin and/or creatinine
greater than UNL
• Evidence of a stable residence • Urine drug screen positive for substance of abuse other than cannabis
• Presence of a referred family able to assist with drug administration and
monitoring
• Pregnant women and women of childbearing potential who did not practise a
medical acceptable form of birth control
• Breastfeeding women
• Individuals requiring inpatient treatment or more intense outpatient treatment
for AD
• Participation in any clinical trial within the last 60 days
• Court-mandated participation in alcohol treatment or pending incarceration
DSM IV, Diagnostic and Statistical Manual of Mental Disorders; HDD, heavy drinking days; AST, aspartate aminotransferase; ALT, alanine aminotransferase;
UNL, upper normal limit.
aHDD is an overall intake of five or more drinks per day for men and of four or more drinks per day for women.
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(TLFB) method (Sobell et al., 1988). The TLFB was admi-
nistered by trained investigators.
Blood and urine laboratory tests included complete blood
count, mean cell volume, bilirubin, aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), alkaline phos-
phatase, γ-glutamyl-transpeptidase, chemistry and urinalysis
for microscopic examination and drug screen. For women, a
urine pregnancy test UbHCG (urine beta human chorionic
gonadotrophin) was performed at screening and during treat-
ment Weeks 4, 8 and 12.
Individuals meeting inclusion/exclusion criteria were
scheduled for the initial treatment visit (Week 1 visit) within
1 week. Subjects were asked to abstain from drinking
alcohol at least for 3 days prior to the initial treatment visit.
Subjects who had significant withdrawal symptoms [diag-
nosed according to the Clinical Institute Withdrawal
Assessment for Alcohol-revised scale (Sullivan et al., 1989)]
were treated with diazepam, but patients who required >10
days of treatment with benzodiazepines were excluded. Thus,
patients started the study after at least 3 and no >10 days of
abstinence from alcohol.
At the baseline visit and at all subsequent visits, a blood
alcohol concentration <5 mg/dl was required. Otherwise, the
visit was rescheduled. At the baseline visit, patients were ran-
domized to one of the three treatment conditions (placebo or
baclofen 10 mg t.i.d. or baclofen 20 mg t.i.d.). Eligible patients
were allocated to one of the treatment groups according to a
computer-generated randomization list produced by the phar-
macist who prepared the drug and the placebo. Participants and
investigators were unaware of treatment assignment. To main-
tain masking, an independent colleague, who did not have any
further role in the study, concealed the randomization codes in
a safe box. For the duration of the study (including also the 4
weeks of follow-up), this colleague could be contacted at any
time to break the blind in case of emergency. Placebo and
baclofen were prepared by a local compounding pharmacy,
which had already prepared medication for our other double-
blind studies. Placebo, baclofen 10 mg and baclofen 20 mg
tablets were identical in size, colour, shape and taste. In the
baclofen 10 mg t.i.d. group, the drug was administered at a
dose of 5 mg t.i.d. for the first 3 days, 10 mg t.i.d. on Days 4–
81 and finally 5 mg t.i.d. for the last 3 days; patients of the
baclofen 20 mg t.i.d. group took a dose of 5 mg t.i.d. for the
first 3 days, a dose of 10 mg t.i.d. on Days 4–7, a dose of 20
mg t.i.d. on Days 8–77, a dose of 10 mg t.i.d. on Days 78–81
and finally, a dose of 5 mg t.i.d. for the last 3 days.
During the study period, in addition to the study medi-
cation, all subjects received brief psychological therapy
designed for the treatment of alcohol-dependent patients
(BRENDA; Starosta et al., 2006) from trained staff. During
the study, BRENDA was employed at each visit for nine ses-
sions of ~30 min. Participants were also encouraged to
attend Alcoholics Anonymous.
At each visit, drinking was recorded using TLFB; concomi-
tant medications, adverse events and general clinical and psy-
chiatric status were recorded. Patients’ interview and pill counts
were used to assess compliance with the study medication.
Statistical analysis
Continuous variables are reported as the medians, inter-
quartile range (IQR) and minimum and maximum values
because of skewed distributions. The IQR was calculated as
the difference between the 75th and 25th percentiles.
Categorical variables are reported as the number or percen-
tage of subjects with the characteristic of interest. The effi-
cacy of baclofen 20 mg and baclofen 10 mg vs. placebo was
evaluated using a random-effect negative binomial regression
model accounting for over dispersion (Hilbe, 2007; Horton
et al., 2007). The outcome variable was the number of drinks
per day evaluated by TLFB, and the predictors were treat-
ment (1 = placebo; 2 = baclofen 10 mg; 3 = baclofen 20 mg),
time of the study (0 = pre-randomization period; 1 = after-
randomization period) and a time × treatment interaction,
which was the main predictor of interest (time = 1 × treat-
ment = 2 for the effect of baclofen 10 mg vs. placebo during
the study and time = 1 × treatment = 3 for the effect of baclo-
fen 20 mg vs. placebo during the study). Effect sizes are
given as incidence rate ratios and 95% confidence intervals.
The data of the patients who dropped out from the study
were not discarded but modelled using maximum likelihood
principles (Schafer and Graham, 2002). Statistical analysis
was performed using STATA version 11.1 (Stata Corp,
College Station, TX, USA).
RESULTS
Out of 94 subjects consecutively screened, 42 satisfied
inclusion criteria and were randomized into the study. These
42 patients had a median (IQR) age of 44 (13) years (range
23–60 years). Out of the 42 subjects randomized, 76% were
males. Table 2 shows study participants’ baseline demo-
graphic characteristics. Fourteen of the 42 patients were ran-
domly allocated to placebo, 14 to baclofen 10 mg t.i.d. (B10
mg) and 14 to baclofen 20 mg t.i.d. (B20 mg). Six patients
in the placebo group dropped out from the study at Days 28,
35, 35, 49, 56 and 84; two patients in the B10 mg group
dropped out at Days 49 and 70; and two patients in the B20
mg dropped out at Days 56 and 84. All the ten dropped-out
patients were lost to follow-up, i.e. they missed three or
more consecutive visits.
Figure 1A–C show the profile plots of drink consumption
in the three study groups. Table 3 reports the incidence rate
ratios obtained from negative binomial regression to test the
efficacy of baclofen vs. placebo. Compared with the patients
allocated to placebo, those allocated to B10 mg obtained a
53% reduction in the number of drinks per day (P < 0.0001)
and patients allocated into the B20 mg group obtained a
68% reduction in the number of drinks per day (P < 0.0001),
with respect to the number of drinks per day during the
Table 2. Baseline characteristics of study participants
Baclofen 10 mg
t.i.d. (n = 14)
Baclofen 20 mg
t.i.d. (n = 14)
Placebo
(n = 14)
Age (years) 45.6
(32.0–60.0)
43.1
(30.0–57.0)
43.1
(23.0–59.0)
Men 12 (86%) 9 (64%) 11 (78%)
Married 8 (57%) 6 (43%) 5 (36%)
Education (≥13
years)
4 (28%) 9 (64%) 10 (71%)
Employed 8 (57%) 8 (57%) 6 (43%)
Data represent number of patients (and percentage) or median (IQR).
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28 days before randomization. The effect of baclofen 20 mg
t.i.d. was greater than that of baclofen 10 mg t.i.d. (P =
0.0214, Wald test), showing a dose–effect relationship.
Table 4 reports the average number of drinks per day before
and after the randomization as estimated by the negative
binomial regression.
No serious or severe side effects leading to drug cessation
were observed, and no patients discontinued treatment
because of side effects. Side effects experienced are shown
in Table 5. One patient randomized to 20 mg t.i.d. experi-
enced drowsiness, weakness, fatigue and muscle pain, which
disappeared after halving the dose. Side effects in other
patients resolved spontaneously within 2 weeks of treatment.
No patient reported euphoria or related pleasant effects
caused by the drug. At drug discontinuation, no new side
effects were observed.
DISCUSSION
This analysis found that oral administration of baclofen, both
at the dose of 10 mg t.i.d. and at that of 20 mg t.i.d., was sig-
nificantly more effective than placebo in reducing daily
alcohol intake, although previous analysis of HDD and AD
in this rather small sample had not shown an effect of baclo-
fen. In addition, the effect of baclofen 20 mg t.i.d. in redu-
cing daily alcohol intake was significantly greater than that
of baclofen 10 mg t.i.d., showing a dose–effect relationship.
This study thus represents a preliminary demonstration of a
baclofen dose–effect relationship in the treatment of alco-
holic patients.
This study confirms previous studies (Addolorato et al.,
2000, 2002, 2007; Flannery et al., 2004; Leggio et al., 2008a,
b) showing an effect of baclofen on alcohol consumption in
alcohol-dependent individuals. The effects of baclofen on
alcohol consumption may depend on its ability to interfere
with neuronal substrates mediating the reinforcing properties
of ethanol throughout GABAB receptor stimulation. GABAB
receptors located in the ventral tegmental area have been
reported to control the activity of mesolimbic dopamine
neurones, which are involved in the regulation of reinforcing
Fig. 1. (A) Number of drinks per day in the placebo group. The outcome
variable is the natural logarithm of the number of drinks consumed in a day and
has 1 added to it to permit the calculation of a logarithm corresponding to 0. The
vertical bar marks the start of the randomized study (Day 28). (B) Number of
drinks per day in the baclofen 10 mg t.i.d. group. Legend as in (A). (C) Number
of drinks per day in the baclofen 20 mg t.i.d. group. Legend as in (A).
Table 3. Effect of baclofen on alcohol consumption
Incidence rate ratio
(95% confidence intervals)
Baclofen 10 mg t.i.d.a 1.16 (0.92–1.46)
Baclofen 20 mg t.i.d.a 0.81 (0.64–1.02)
Start of trial (Day ≥ 28) 0.05* (0.04–0.05)
Baclofen 10 mg t.i.d. after start of the triala 0.47* (0.36–0.61)
Baclofen 20 mg t.i.d. after start of the triala 0.32* (0.23–0.44)
The outcome variable is the number of drinks per day, and placebo is the
reference group for all comparisons. The effects of baclofen 10 mg t.i.d. and
baclofen 20 mg t.i.d. after randomization are those of interest. Effects sizes
were obtained from a negative binomial regression model accounting for
over dispersion (see Statistical analysis for details).
avs. placebo
*P < 0.001.
Table 4. Average number of drinks per day before and after randomization
Average number of drinks
(95% confidence intervals)
Pre-randomization Post-randomization
Placebo 11.98 (9.05–14.91) 0.55 (0.40–0.70)
Baclofen 10 mg t.i.d. 13.91 (10.37–17.46) 0.30 (0.21–0.39)
Baclofen 20 mg t.i.d. 9.65 (7.30–12.01) 0.14 (0.09–0.19)
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properties of addictive drugs, including alcohol (Colombo
et al., 2004; Di Chiara, 1995; Koob et al., 1998; Weiss and
Porrino, 2002).
The dose–response effect observed is consistent with pre-
vious preclinical and clinical observations. Pre-treatment with
baclofen resulted in a dose-dependent suppression of extinction
responding for alcohol in alcohol-preferring rats (Colombo
et al., 2003), where extinction responding for alcohol was
defined as the maximal number of lever responses reached by
each rat in the absence of alcohol reinforcement. A dose-
dependent decrease of ethanol self-administration has also been
observed in alcohol-dependent rats treated with increasing
doses of baclofen (Walker and Koob, 2007).
In our previous studies, we selected the minimum thera-
peutic dose of 10 mg t.i.d. to avoid possible side effects
(Addolorato et al., 2000, 2002). However, baclofen is used at
higher doses to control spasticity (i.e. 80 mg/day). Moreover,
recent studies with other addicted populations have used
higher doses, such as 20 mg t.i.d. in cocaine-dependent indi-
viduals (Kahn et al., 2009; Shoptaw et al., 2003) and 20 mg
q.i.d. in nicotine-dependent individuals (Franklin et al.,
2009). Furthermore, anecdotal reports describe how high
doses of baclofen (up to 140 and 270 mg/day) resulted in a
marked decrease in alcohol intake and alcohol craving in
patients not responding to lower doses (Ameisen, 2005;
Bucknam, 2007).
Our previous trial showed a significant effect of baclofen
10mg t.i.d. in alcohol-dependent patients with liver cirrhosis.
We can speculate that, for patients with liver disease [who
were not recruited in the study of Garbutt et al. (2010) that
had a negative result for 10 mg t.i.d.], a lower dose may be
sufficient to show an effect of baclofen because some 15%
of baclofen metabolism depends on the liver, while a higher
dose is required when liver disease is not present.
The present study provides additional evidence of the
safety of baclofen at the dose of 20 mg t.i.d. when adminis-
tered to alcoholics. Notably, a recent human laboratory study
showed the safety of baclofen (0, 40 and 80 mg) when
co-administered with alcohol (Evans and Bisaga, 2009).
Moreover, our study showed no evidence of potential addic-
tive properties of baclofen when administered to an addictive
population, such as alcohol-dependent individuals, as shown
by the absence of a withdrawal syndrome and the lack of
euphoric effects. This observation is consistent with the lack
of potential addictive properties of baclofen at doses of
20mg t.i.d. and 20 mg q.i.d., when administered to
individuals with cocaine dependence (Shoptaw et al., 2003;
Kahn et al., 2009) and nicotine dependence (Franklin et al.,
2009), respectively.
Finally, in the present study, there was a lower, although not
statistically significant, number of drop outs in the two baclo-
fen groups than in the placebo group. The safety of baclofen
and its efficacy with respect to placebo can explain the lower
number of drop outs in baclofen-treated patients, an obser-
vation consistent with previous pharmacological trials in psy-
chiatric patients (Krupitsky et al., 1993) and with our previous
baclofen alcohol studies (Addolorato et al., 2002, 2007).
Our study has limitations. First, the results reported here
represent a secondary analysis conducted in a small sample.
The main IBIS study was markedly underpowered and, as
mentioned before, this led to the lack of the planned sample
size able to show a possible medication effect on the planned
outcomes (HDD, AD and craving score); specifically, results
did not show significant differences in the primary outcomes
measures. Nevertheless, this secondary analysis shows that
there is an effect of baclofen on some drinking outcomes,
with a dose–response effect, thus providing much needed
data necessary for potential future large clinical trials.
Secondly, the application of a ‘day-by-day’ model prevented
us from analysing other outcomes such as HDD, AD, time to
first lapse, time to first relapse, craving, anxiety and markers
of alcohol abuse (i.e. AST, ALT) because these data were
not available on a daily basis.
In conclusion, the present study provides further evidence
that baclofen is an effective and safe pharmacotherapy for
AD and provides the first evidence of a possible dose–
response effect. Future large studies testing different doses of
baclofen and targeting alcoholics with different degrees of
severity of dependence should be performed to further inves-
tigate the role of baclofen in AD.
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